학술논문

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
Document Type
Journal
Source
LANCET ONCOLOGY; NOV 2022, 23 11, p1398-p1408, 11p.
Subject
Language
English
ISSN
14745488